During the past decade, Rochester Clinical Research, Inc. conducted 103 clinical trials. In the 10-year time frame, 103 clinical trials started and 76 clinical trials were completed, i.e. on average, 73.8% percent of trials that started reached the finish line to date. In the past 5 years, 55 clinical trials started and 53 clinical trials were completed. i.e. 96.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Rochester Clinical Research, Inc." #1 sponsor was "Pfizer" with 25 trials, followed by "Eli Lilly and Company" with 13 trials sponsored, "ModernaTX, Inc." with 6 trials sponsored, "BioNTech SE" with 5 trials sponsored and "Emergent BioSolutions" with 5 trials sponsored. Other sponsors include 100 different institutions and companies that sponsored additional 73 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Rochester Clinical Research, Inc." #1 collaborator was "Pfizer" with 5 trials as a collaborator, "Biomedical Advanced Research and Development Authority" with 2 trials as a collaborator, "CoLucid Pharmaceuticals" with 2 trials as a collaborator, "Department of Health and Human Services" with 2 trials as a collaborator and "Allergan Sales, LLC" with 1 trials as a collaborator. Other collaborators include 15 different institutions and companies that were collaborators in the rest 25 trials.

According to Clinical.Site data, the most researched conditions in "Rochester Clinical Research, Inc." are "Migraine" (14 trials), "Influenza" (11 trials), "Obesity" (6 trials), "COVID-19" (5 trials) and "Herpes Labialis" (5 trials). Many other conditions were trialed in "Rochester Clinical Research, Inc." in a lesser frequency.

Most popular intervention types in "Rochester Clinical Research, Inc." are "Drug" (82 trials), "Biological" (71 trials), "Other" (18 trials), "Device" (8 trials) and "Behavioral" (7 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (70 trials), "Rimegepant" (5 trials), "Ad26.COV2.S" (4 trials), "Galcanezumab" (4 trials) and "VLA15" (4 trials). Other intervention names were less common.

The vast majority of trials in "Rochester Clinical Research, Inc." are 146 trials for "All" genders, 10 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Rochester Clinical Research, Inc.". undefined are not yet recruiting, 10 are recruiting, 16 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 126 completed trials in Rochester Clinical Research, Inc., undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Rochester Clinical Research, Inc., 11 "Phase 1" clinical trials were conducted, 59 "Phase 2" clinical trials and 86 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 6 trials that are defined as “Not Applicable".